JAK inhibitors in lichen planus: a review of pathogenesis and treatments

References

• Di Lernia V. Targeting the IFN-γ/CXCL10 pathway in lichen planus. Med Hypotheses. 2016;92:60–61.
   PubMed Web of Science ®Google Scholar
• Weston G, Payette M. Update on lichen planus and its clinical variants. Int J Womens Dermatol. 2015;1(3):140–149.
   PubMedGoogle Scholar
• Damsky W, Wang A, Olamiju B, et al. Treatment of severe lichen planus with the JAK inhibitor tofacitinib. J Allergy Clin Immunol. 2020;145(6):1708–1710.
   PubMed Web of Science ®Google Scholar
• Yang CC, Khanna T, Sallee B, et al. Tofacitinib for the treatment of lichen planopilaris: a case series. Dermatol Ther. 2018;31(6):e12656.
   PubMed Web of Science ®Google Scholar
• Bilgili SG, et al. The prevalence of skin diseases among the geriatric patients in Eastern Turkey. J Pak Med Assoc. 2012;62(6):535.
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Sugerman PB, Savage NW, et al. Intra‐epithelial CD8+ T cells and basement membrane disruption in oral lichen planus. J Oral Pathol Med. 2002;31(1):23–27.
   PubMed Web of Science ®Google Scholar
• Rao UK. Oral lichen planus: an update on pathogenesis and treatment. J Oral Maxillofacial Pathol. 2011;15(2):127–132.
   PubMedGoogle Scholar
• Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med. 2002;13(4):350–365.
   PubMedGoogle Scholar
• Ke Y, Dang E, Shen S, et al. Semaphorin4D drives CD8+ T-cell lesional trafficking in oral lichen planus via CXCL9/CXCL10 upregulations in oral keratinocytes. J Invest Dermatol. 2017;137(11):2396–2406.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhang D, Han Q, et al. Role of distinct CD 4+ T helper subset in pathogenesis of oral lichen planus. J Oral Pathol Med. 2016;45(6):385–393.
   PubMed Web of Science ®Google Scholar
• Piccinni M-P, Lombardelli L, Logiodice F, et al. Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus. Oral Dis. 2014;20(2):212–218.
   PubMed Web of Science ®Google Scholar
• Schmidt T, Solimani F, Pollmann R, et al. TH1/TH17 cell recognition of desmoglein 3 and bullous pemphigoid antigen 180 in patients with lichen planus. J Allergy Clin Immunol. 2018;142(2):669–672. e7.
   PubMed Web of Science ®Google Scholar
• Wenzel J, Scheler M, Proelss J, et al. Type I interferon‐associated cytotoxic inflammation in lichen planus. J Cutan Pathol. 2006;33(10):672–678.
   PubMed Web of Science ®Google Scholar
• Schroder K, Hertzog PJ, Ravasi T, et al. Interferon‐γ: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163–189.
   PubMed Web of Science ®Google Scholar
• Pietschke K, Holstein J, Meier K, et al. The inflammation in cutaneous lichen planus is dominated by IFN‐ϒ and IL‐21—a basis for therapeutic JAK1 inhibition. Exp Dermatol. 2021;30(2):262–270.
   PubMed Web of Science ®Google Scholar
• Shao S, Tsoi LC, Sarkar MK, et al. IFN-γ enhances cell-mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus. Sci Transl Med. 2019;11(511):eaav7561.
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Gadina M. Jakpot! new small molecules in autoimmune and inflammatory diseases. Exp Dermatol. 2014;23(1):7–11.
   PubMed Web of Science ®Google Scholar
• Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129(9):2299–2302.
   PubMed Web of Science ®Google Scholar
• Plante J, Eason C, Snyder A, et al. Tofacitinib in the treatment of lichen planopilaris: a retrospective review. J Am Acad Dermatol. 2020;83(5):1487–1489.
   PubMed Web of Science ®Google Scholar
• Iorizzo M, Haneke E. Tofacitinib as treatment for nail lichen planus associated with alopecia universalis. JAMA Dermatol. 2021;157(3):352–353.
   PubMed Web of Science ®Google Scholar
• Moussa A, Colla T, Morrison B, et al. Effective treatment of oral lichen planus with the JAK inhibitor baricitinib. Aust J Dermatology. 2022;63(2):276–277.
   PubMed Web of Science ®Google Scholar
• Pünchera J, Laffitte E. Treatment of severe nail lichen planus with baricitinib. JAMA Dermatol. 2022;158(1):107–108.
   PubMed Web of Science ®Google Scholar
• Moussa A, Bhoyrul B, Asfour L, et al. Treatment of lichen planopilaris with baricitinib: a retrospective study. J Am Acad Dermatol. 2022;87(3):663–666.
   PubMed Web of Science ®Google Scholar
• Kreuter A, Licciardi‐Fernandez MJ, Burmann SN, et al. Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia. Clin Exp Dermatol. 2022;47(4):787–788.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):1–10.
   PubMed Web of Science ®Google Scholar
• Duggan S, Keam SJ. Upadacitinib: first approval. Drugs. 2019;79(16):1819–1828.
   PubMed Web of Science ®Google Scholar
• Klünder B, Mittapalli RK, Mohamed M-EF, et al. Population pharmacokinetics of upadacitinib using the immediate-release and extended-release formulations in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I–III clinical trials. Clin Pharmacokinet. 2019;58(8):1045–1058.
   PubMed Web of Science ®Google Scholar
• Balestri R, Bortolotti R, Rech G, et al. Treatment of oral erosive lichen planus with upadacitinib. JAMA Dermatol. 2022;158(4):457–458.
   PubMed Web of Science ®Google Scholar
• Kooybaran NR, Petzold G, Ströbel P, et al. Alleviation of erosive oral and esophageal lichen planus by the JAK1 inhibitor upadacitinib. J Dtsch Dermatol Ges. 2021;19(12):1778–1780.
   PubMedGoogle Scholar
• Seiringer P, Lauffer F, Pilz A, et al. Tofacitinib in hypertrophic lichen planus. Acta Derm Venereol. 2020;100(14):adv00220.
   PubMedGoogle Scholar
• Kooybaran NR, Petzold G, Schön MP, et al. Esophageal lichen planus successfully treated with the JAK1/3 inhibitor tofacitinib. Journal Der Deutschen Dermatologischen Gesellschaft J German Soc Dermatol. 2022;20(6):858–860.
   Web of Science ®Google Scholar
• Brumfiel CM, Patel MH, Severson KJ, et al. Ruxolitinib cream in the treatment of cutaneous lichen planus: a prospective, open-label study. J Invest Dermatol. 2022;142(8):2109–2116.e4.
   PubMed Web of Science ®Google Scholar